Cancer vaccine - Coley/GlaxoSmithKline

Drug Profile

Cancer vaccine - Coley/GlaxoSmithKline

Alternative Names: VaxImmune - Coley/GlaxoSmithKline

Latest Information Update: 23 Jul 2010

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Coley Pharmaceutical Group; GlaxoSmithKline
  • Class Cancer vaccines
  • Mechanism of Action Immunostimulants; Toll-like receptor 9 agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • No development reported Breast cancer; Lung cancer; Prostate cancer

Most Recent Events

  • 21 Jun 2006 Phase-I clinical trials in Prostate cancer in Belgium (unspecified route)
  • 21 Jun 2006 Phase-II clinical trials in Breast cancer in Belgium (unspecified route)
  • 21 Jun 2006 Preclinical trials in Lung cancer in Belgium (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top